Addressing Disability in Cancer Survivors
Journal of Clinical Oncology · 01.07.2024 · 42 (19) · 2239-2241
DOI: 10.1200/jco.24.00479 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2024. Verfasst von Rachelle Brick und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD. Hauptthemen laut MEDLINE: Cancer Survivors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
In the article that accompanies this editorial, Cao and colleagues present the prevalence and correlates of mobility and self-care disability from self-identified cancer survivors in the 2017–2022 Behavioral Risk Factor Surveillance System and show that over one quarter of cancer survivors reported a mobility disability. This work paves the way for research on the prevention, mitigation, and resolution of cancer-related disability, and emphasizes the importance of incorporating multi-level and multidimensional measures of disability in population research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD.
ORCID-Profile: Rachelle Brick, Emily S Tonorezos
Förderung
- Intramural NIH HHS
Zitieren
APA
Brick, R., & Tonorezos, E. S. (2024). Addressing Disability in Cancer Survivors. Journal of Clinical Oncology, 42(19), 2239-2241. https://doi.org/10.1200/jco.24.00479
Vancouver
Brick R, Tonorezos ES. Addressing Disability in Cancer Survivors. Journal of Clinical Oncology. 2024;42(19):2239-2241. doi:10.1200/jco.24.00479
BibTeX
@article{Brick2024,
author = {Brick, Rachelle and Tonorezos, Emily S},
title = {Addressing Disability in Cancer Survivors},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {19},
pages = {2239--2241},
doi = {10.1200/jco.24.00479}
}
EUVIMED